AlphaCentric Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

AlphaCentric Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-245,000	Closed	-$1.27M	–	292
2024 Q3	$1.27M	Hold	245,000	–	–	0.95%	34
2024 Q2	$630K	Hold	245,000	–	–	0.46%	69
2024 Q1	$1.21M	Buy	245,000 +25,000	+11%	+$148K	0.73%	55
2023 Q4	$1.93M	Buy	220,000 +30,000	+16%	+$246K	1.3%	24
2023 Q3	$2.18M	Buy	+190,000	New	+$3.65M	1.24%	21
2021 Q4	$1.06M	Buy	65,000 +58,500	+900%	+$975K	0.31%	30
2021 Q3	$181K	Hold	6,500	–	–	0.05%	114
2021 Q2	$193K	Hold	6,500	–	–	0.05%	107
2021 Q1	$182K	Buy	6,500 +4,000	+160%	+$111K	0.06%	98
2020 Q4	$71K	Buy	+2,500	New	+$64.8K	0.03%	163

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

AlphaCentric Advisors's RVNC Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 245,000 shares — an estimated $1.27M sold.

AlphaCentric Advisors first reported a position in RVNC in Q4 2020 and held it in 10 quarters. The position peaked at $2.18M in Q3 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

AlphaCentric Advisors reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
AlphaCentric Advisors sold 245,000 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $1.27M.
AlphaCentric Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 10 quarters.
AlphaCentric Advisors's Revance Therapeutics, Inc. position peaked at $2.18M in Q3 2023.
173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.